Trial Profile
A Phase 2b Study of KW-6356 in Subjects With Parkinson's Disease on Treatment With Levodopa-containing Preparations
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2022
Price :
$35
*
At a glance
- Drugs Sipagladenant (Primary)
- Indications Parkinson's disease
- Focus Therapeutic Use
- Sponsors Kyowa Kirin
- 18 Sep 2022 Results of post-hoc analysis assessing potential benefits for PD patients with sleep problems presented at the 26th International Congress of Parkinson's Disease and Movement Disorders
- 04 Sep 2020 Status changed from active, no longer recruiting to completed.
- 26 Nov 2019 Status changed from recruiting to active, no longer recruiting.